Skip to main content

Dexcom income statement

  • DXCM · Nasdaq
  • Medical devices
  • Health Care Equipment
  • S&P 500
$83.33+2.38%Close 13 Nov 2026 · Market value $30.72B

Dexcom reported revenue of $4.66 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 15.6% from fiscal 2024. Net income was $836 million and diluted earnings per share $2.09.

From Dexcom's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025. TTM is the last four reported quarters added up.

Annual

Dexcom income statement, annual
USDFY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Revenue$29.69M$48.60M$76.30M$99.90M$160.0M$259.2M$402.0M$573.3M$718.5M$1.03B$1.48B$1.93B$2.45B$2.91B$3.62B$4.03B$4.66B$5.10B
Revenue growth—+63.7%+57.0%+30.9%+60.2%+62.0%+55.1%+42.6%+25.3%+43.6%+43.1%+30.5%+27.1%+18.8%+24.5%+11.3%+15.6%—
Cost of revenue$26.03M$30.20M$40.40M$53.30M$59.90M$82.90M$123.6M$194.9M$226.4M$367.7M$544.5M$646.6M$768.0M$1.03B$1.33B$1.59B$1.86B$1.87B
Gross profit$3.66M$18.40M$35.90M$46.60M$100.1M$176.3M$278.4M$378.4M$492.1M$663.9M$931.5M$1.28B$1.68B$1.88B$2.29B$2.44B$2.80B$3.24B
Gross margin12.3%37.9%47.1%46.6%62.6%68.0%69.3%66.0%68.5%64.4%63.1%66.4%68.6%64.7%63.2%60.5%60.1%63.4%
Research and development$14.29M$23.20M$29.60M$38.30M$44.80M$69.40M$137.5M$156.1M$185.4M$199.7M$273.5M$359.9M$517.1M$484.2M$505.8M$552.4M$599.1M$608.1M
Selling, general and administrative$35.20M$40.50M$51.10M$64.00M$84.20M$128.4M$198.0M$286.2M$349.2M$432.8M$515.7M$618.2M$810.5M$1.01B$1.19B$1.29B$1.29B$1.41B
Operating expenses$49.49M$63.70M$80.70M$102.3M$129.0M$197.8M$335.5M$442.3M$534.6M$850.2M$789.2M$980.6M$1.41B$1.49B$1.69B$1.84B$1.89B$2.01B
Operating income−$45.83M−$45.30M−$44.80M−$55.70M−$28.90M−$21.50M−$57.10M−$63.90M−$42.50M−$186.3M$142.3M$299.5M$265.8M$391.2M$597.7M$600.0M$911.8M$1.22B
Operating margin−154%−93.2%−58.7%−55.8%−18.1%−8.3%−14.2%−11.1%−5.9%−18.1%9.6%15.5%10.9%13.4%16.5%14.9%19.6%24.0%
Interest expense$8.04M$1.50M$11.00K$200.0K$900.0K$800.0K$400.0K$700.0K$12.80M$22.70M$60.30M$17.70M$18.80M$14.70M$16.40M$14.90M$14.30M$9.50M
Income before tax—−$55.20M−$44.70M−$55.80M−$29.80M−$22.30M−$57.50M−$64.90M−$48.60M−$126.5M$104.2M$297.9M$256.8M$390.8M$710.4M$709.0M$1.09B$1.26B
Income tax expense—$31.00K−$32.00K−$1.30M$0.00$100.0K$100.0K$700.0K$1.60M$600.0K$3.10M−$251.8M$39.90M$49.60M$168.9M$132.8M$252.1M$271.4M
Effective tax rate—−0.1%0.1%2.3%0.0%−0.4%−0.2%−1.1%−3.3%−0.5%3.0%−84.5%15.5%12.7%23.8%18.7%23.2%21.5%
Net income−$53.52M−$55.20M−$44.70M−$54.50M−$29.80M−$22.40M−$57.60M−$65.60M−$50.20M−$127.1M$101.1M$549.7M$216.9M$341.2M$541.5M$576.2M$836.3M$991.0M
Net margin−180%−114%−58.6%−54.6%−18.6%−8.6%−14.3%−11.4%−7.0%−12.3%6.8%28.5%8.9%11.7%14.9%14.3%17.9%19.4%
EPS · diluted—−$0.24−$0.17−$0.20−$0.10−$0.07−$0.18−$0.20−$0.15−$0.36$0.27$1.33$0.53$0.82$1.30$1.42$2.09$2.53
Diluted weighted average shares—228M262M275M284M301M319M334M345M353M369M420M429M428M426M413M406M392M
Basic weighted average shares—228M262M275M284M301M319M334M345M353M364M378M387M389M386M394M390M382M
EBITDA−$43.46M−$42.90M−$41.00M−$49.10M−$21.90M−$13.10M−$46.30M−$48.90M−$26.40M−$157.2M$191.0M$366.6M$367.8M$547.1M$783.7M$817.7M$1.16B$1.50B
EBITDA margin−146%−88.3%−53.7%−49.1%−13.7%−5.1%−11.5%−8.5%−3.7%−15.2%12.9%19.0%15.0%18.8%21.6%20.3%25.0%29.4%
Depreciation & amortization$2.37M$2.40M$3.80M$6.60M$7.00M$8.40M$10.80M$15.00M$16.10M$29.10M$48.70M$67.10M$102.0M$155.9M$186.0M$217.7M$251.8M$275.0M
Stock-based compensation$8.37M$9.40M$13.50M$18.40M$24.60M$50.00M$82.70M$110.8M$106.2M$101.9M$102.7M$119.4M$113.4M$126.5M$150.8M$170.4M$159.6M$154.1M

Quarterly

Dexcom income statement, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$1.03B$921.0M$1.00B$994.2M$1.11B$1.04B$1.16B$1.21B$1.26B$1.19B$1.31B$1.34B
Cost of revenue$377.9M$359.1M$377.6M$400.4M$457.7M$447.0M$468.3M$477.9M$466.9M$441.6M$478.4M$480.1M
Gross profit$656.6M$561.9M$626.7M$593.8M$655.8M$589.0M$688.8M$731.4M$792.7M$750.3M$830.0M$864.4M
Gross margin63.5%61.0%62.4%59.7%58.9%56.9%59.5%60.5%62.9%62.9%63.4%64.3%
Research and development$136.1M$141.5M$136.0M$135.4M$139.5M$145.2M$148.2M$157.5M$148.2M$145.3M$153.0M$161.6M
Selling, general and administrative$303.6M$319.3M$332.7M$306.4M$327.4M$310.1M$328.0M$331.4M$321.5M$349.7M$358.7M$375.6M
Operating expenses$439.7M$460.8M$468.7M$441.8M$466.9M$455.3M$476.2M$488.9M$469.7M$495.0M$511.7M$537.2M
Operating income$216.9M$101.1M$158.0M$152.0M$188.9M$133.7M$212.6M$242.5M$323.0M$255.3M$318.3M$327.2M
Operating margin21.0%11.0%15.7%15.3%17.0%12.9%18.4%20.1%25.6%21.4%24.3%24.3%
Interest expense$3.90M$3.70M$3.80M$3.70M$3.70M$3.70M$3.80M$3.70M$3.10M$2.10M$2.20M$2.10M
Income before tax$246.2M$132.5M$187.8M$177.4M$211.3M$154.3M$241.1M$352.3M$340.7M$269.5M$317.5M$334.7M
Income tax expense−$10.10M−$13.90M$44.30M$42.80M$59.60M$48.90M$61.30M$68.50M$73.40M$70.00M$68.40M$59.60M
Effective tax rate−4.1%−10.5%23.6%24.1%28.2%31.7%25.4%19.4%21.5%26.0%21.5%17.8%
Net income$256.3M$146.4M$143.5M$134.6M$151.7M$105.4M$179.8M$283.8M$267.3M$199.5M$249.1M$275.1M
Net margin24.8%15.9%14.3%13.5%13.6%10.2%15.5%23.5%21.2%16.7%19.0%20.5%
EPS · diluted$0.61$0.36$0.35$0.34$0.37$0.27$0.45$0.70$0.67$0.51$0.64$0.72
Diluted weighted average shares417M417M417M410M407M408M408M407M399M394M390M384M
Basic weighted average shares384M390M399M394M391M391M392M391M387M385M382M375M
EBITDA$269.4M$153.6M$210.1M$207.3M$246.7M$193.7M$275.6M$306.1M$388.2M$322.4M$386.5M$401.7M
EBITDA margin26.0%16.7%20.9%20.9%22.2%18.7%23.8%25.3%30.8%27.0%29.5%29.9%
Depreciation & amortization$52.50M$52.50M$52.10M$55.30M$57.80M$60.00M$63.00M$63.60M$65.20M$67.10M$68.20M$74.50M
Stock-based compensation$36.90M$39.00M$44.70M$43.40M$43.30M$34.20M$45.30M$45.10M$35.00M$43.30M$39.00M$36.80M

The main figures as JSON and plain text. See data and methodology.

DXCM in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.